Philipp Freese - Mainz Biomed Chief Officer
| MYNZ Stock | USD 0.23 0.02 9.52% |
Insider
Philipp Freese is Chief Officer of Mainz Biomed BV
| Age | 41 |
| Address | Robert Koch Strasse 50, Mainz, Germany, 55129 |
| Phone | 49 6131 554 2860 |
| Web | https://mainzbiomed.com |
Mainz Biomed Management Efficiency
The company has return on total asset (ROA) of (0.9924) % which means that it has lost $0.9924 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (43.3371) %, meaning that it created substantial loss on money invested by shareholders. Mainz Biomed's management efficiency ratios could be used to measure how well Mainz Biomed manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -2.3 in 2024. Return On Capital Employed is likely to rise to -4.1 in 2024. At this time, Mainz Biomed's Non Current Assets Total are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 7.7 M in 2024, whereas Total Assets are likely to drop slightly above 10.4 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Tony Benson | Applied DNA Sciences | N/A | |
| Zvi David | DarioHealth Corp | 63 | |
| Ron Kalfus | MDxHealth SA ADR | 50 | |
| John Boniface | Sera Prognostics | 62 | |
| Jeffrey Eberwein | Star Equity Holdings | 53 | |
| Wim Criekinge | MDxHealth SA ADR | 52 | |
| Hanjoon Kim | Standard Biotools | 53 | |
| Martin Shirley | Star Equity Holdings | 61 | |
| Bob Halbert | Star Equity Holdings | N/A | |
| John DSA | Inotiv Inc | 57 | |
| Claire Sears | Neuronetics | N/A | |
| Jonathan Behr | ENDRA Life Sciences | N/A | |
| Matt Stauffer | Biodesix | N/A | |
| Jeffrey Bojar | Biodesix | N/A | |
| Mark Spearman | Standard Biotools | N/A | |
| Peter DeNardo | Standard Biotools | N/A | |
| Dr III | Biodesix | 53 | |
| Hannah Bible | Star Equity Holdings | 43 | |
| Kimberly Beaty | Inotiv Inc | N/A | |
| Sean MD | Sera Prognostics | N/A | |
| Kara Thornton | Neuronetics | N/A | |
Management Performance
| Return On Equity | -43.34 | ||||
| Return On Asset | -0.99 |
Mainz Biomed BV Leadership Team
Elected by the shareholders, the Mainz Biomed's board of directors comprises two types of representatives: Mainz Biomed inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mainz. The board's role is to monitor Mainz Biomed's management team and ensure that shareholders' interests are well served. Mainz Biomed's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mainz Biomed's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Corinna Gorges, Head RD | ||
| Chris PMP, Chief Officer | ||
| Frank KriegSchneider, Chief Officer | ||
| Darin Leigh, Chief Officer | ||
| Philipp Freese, Chief Officer | ||
| Petra Ploesser, Head Quality | ||
| Guido Baechler, CEO Director | ||
| William Caragol, Chief Officer | ||
| Stefan Erlach, Head Resources | ||
| Christopher PMP, Chief Officer | ||
| William CPA, Chief Officer | ||
| Moritz Eidens, Chief Director |
Mainz Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Mainz Biomed a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -43.34 | ||||
| Return On Asset | -0.99 | ||||
| Operating Margin | (18.83) % | ||||
| Current Valuation | 21.7 M | ||||
| Shares Outstanding | 64.04 M | ||||
| Shares Owned By Insiders | 20.21 % | ||||
| Shares Owned By Institutions | 0.88 % | ||||
| Number Of Shares Shorted | 1.52 M | ||||
| Price To Book | 1.72 X | ||||
| Price To Sales | 15.71 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Mainz Stock Analysis
When running Mainz Biomed's price analysis, check to measure Mainz Biomed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mainz Biomed is operating at the current time. Most of Mainz Biomed's value examination focuses on studying past and present price action to predict the probability of Mainz Biomed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mainz Biomed's price. Additionally, you may evaluate how the addition of Mainz Biomed to your portfolios can decrease your overall portfolio volatility.